Nivolumab: Five-Year Survival for Melanoma, RCC, and NSCLC

​ Five-year overall survival results have now been revealed for nivolumab in advanced melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC). "We report, to our knowledge, the longest combined clinical follow-up for patients with multiple cancer types receiving any anti–PD-L1 drug," the researchers comment in their secondary analysis of data from the phase I CA209-003 trial and expansion cohorts. This trial was the first multidose trial of nivolumab, an immunotherapy drug t...
Continue reading

Pembrolizumab After Locally Ablative Therapy in NSCLC: Joshua Bauml, MD

Locally ablative therapy, which consists of surgery, radiation, and other definitive treatments at all sites of metastasis, has shown efficacy in oligometastatic non-small cell lung cancer (NSCLC). Given that immunotherapy has also shown efficacy in NSCLC, Joshua Bauml, MD, and colleagues at the University of Pennsylvania's Perelman School of Medicine investigated the combination of locally ablative therapy with pembrolizumab (Keytruda®, Merck). The investigators found that adding pembrolizumab ...
Continue reading

Metabolomic Biomarkers Predict Lung Cancer Type, Survival

Investigators are utilizing magnetic resonance spectroscopy to identify metabolomic biomarkers that can predict type, stage, and survival in patients with early-stage lung cancer. Due to lack of early screening methods, lung cancer is commonly not diagnosed until the later stages, resulting in a mortality rate of over 70%. Low-dose spiral computed tomography (LDCT) can detect small lung nodules but is not considered an effective screening tool due to its high cost and radiation hazards. The rese...
Continue reading

NSCLC: Pembrolizumab Following Locally Ablative Therapy

​ A phase 2 clinical trial reports that the addition of pembrolizumab (Keytruda®, Merck) following locally ablative therapy for oligometastatic non-small cell lung cancer (NSCLC) improves median progression-free survival compared with historical data. About 7% of patients with NSCLC have oligometastatic disease, a state of limited systemic metastasis that could be cured by means of locally ablative therapy. A treatment consisting of surgery and radiation at all sites of metastasis, locally ablat...
Continue reading

Ramucirumab/Pembrolizumab in Patients With NSCLC, Gastric Cancer, or Urothelial Carcinoma

A phase 1a/b trial (NCT02443324) reports that ramucirumab in conjunction with pembrolizumab is effective in patients with previously treated advanced non-small cell lung cancer (NSCLC), gastroesophageal cancer, or urothelial carcinomas. Ramucirumab, a monoclonal antibody, blocks vascular endothelial growth factor receptor 2 (VEGFR2), which allows cancer cells to grow and metastasize. Pembrolizumab is also a monoclonal antibody, but it works by blocking programmed cell death protein-1 (PD-1), in ...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.